Current Enrolling Studies | UnityPoint Health - Peoria

Currently Enrolling Clinical Studies

ASCENT COPD:

(COPD study ) This study is a double-blind randomized study to evaluate the effect of Aclidinium Bromide (Tudorza Pressair) on long-term Cardiovascular Safety and COPD exacerbations in patients with moderate to very severe COPD. For more information and to see if you may qualify for this study, please contact Natalie at 309-672-4767.  The Principle Investigator for this study is Dr. Karamchandani

PIONEER:

(Diabetic study)  This is an 18 month study Phase 2 study to evaluate the efficacy and long-term safety of oral Semaglutide versus Sitagliptin as add-on to 1-2 oral anti-diabetic drugs (OAD)s in subjects with type 2 diabetes.  For more information and to see if you may qualify for this study, please contact Deanna at 309-672-4808 or Linda at 309-672-3156.  The Principle Investigator for this study is Dr. Trachtenbarg.

TERRANOVA:

(COPD study)  This is a phase 3, randomized, 56 week study to evaluate the efficacy and safety of 3 doses of Benralizumab (MEDI-563) in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) with a history of COPD Exacerbations (Terranova). For more information and to see if you may qualify for this study, please contact Natalie at 309-672-4767.  The Principle Investigator for this study is Dr. Kashyap.

PARAGON:

(Heart Failure Study) This is a multi-center randomized, double-blind study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV), please contact Linda at 309-672-3156.  Principle Investigator for this study is Dr. Adler.

REDUCE IT:

(Triglyceride Study) This is a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for cardiovascular Disease. For more information and to see if you may qualify for this study, please contact Deanna at 309-672-4808.  The Principle Investigator for this study is Dr. Adler.

REALWORLD:

(Diabetic Study) This is an open-label randomized study to assess the clinical and health outcomes of Toujeo compared to commercially available basal insulin for initiation of therapy in insulin na├»ve patients with uncontrolled type 2 diabetes mellitus.  For more information and to see if you may qualify for this study, please contact Linda at 309-672-3156.  The Principal Investigator for this study is Dr. Trachtenbarg.

PIONEER-HF:

(Heart Failure)  This is a 8 week study to evaluate the effect of Sacubitril and Valsartan (LCZ696) versus Enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF).   For more information about this study, please contact Linda at 309-672-3156.  The Principal Investigator for this study is Dr. Adler.

TANGO:

(Osteoarthritis) This is a Phase 3 randomized, double-blind study of the long-term safety and efficacy of subcutaneous administration of a Biologic Tanezumab in subjects with Osteoarthritis of the hip of knee.  For more information and to see if you may qualify for this study, please contact Deanna at 309-672-4808.  The Principle investigator for this study is Dr. Hanna.

ADAPT:

This is a Phase 4 open label study of Serum Infliximab Concentrations for efficacy and safety of dose escalation in Pediatric Patients with Inflammatory Bowel Disorder.  For more information and to see if you may qualify for this study, please contact Linda at 309-672-3156.  The Principal Investigator for this study is Dr. Khaled.

C-DIFFENSE:

(C-Diff Vaccination) This is a vaccination study for patients that have been hospitalized twice in the last 12 months and have also received an antibiotic within the past 12 months.  It is to show efficacy, immunogenicity, and safety of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C-Difficile Infection.   For more information and to see if you may qualify for this study, please contact Linda at 309-672-3156.  The Principal Investigator for this study is Dr. Trachtenbarg.